References
- Azzouni F, Godoy A, Li Y, Mohler J. 2012. The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseases. Adv Urol. 2012:530121.
- Eicheler W, Tuohimaa P, Vilja P, Adermann K, Forssmann WG, Aumuller G. 1994. Immunocytochemical localization of human 5 alpha-reductase 2 with polyclonal antibodies in androgen target and non-target human tissues. J Histochem Cytochem. 42(5):667–675.
- Ho CH, Sood T, Zito PM. 2020. Androgenetic alopecia. Treasure Island, FL, USA: StatPearls Publishing.
- Jung JY, Yeon JH, Choi JW, Kwon SH, Kim BJ, Youn SW, Park KC, Huh CH. 2014. Effect of dutasteride 0.5 mg/d in men with androgenetic alopecia recalcitrant to finasteride. Int J Dermatol. 53(11):1351–1357.
- Kaufman KD. 2002. Androgens and alopecia. Mol Cell Endocrinol. 198(1-2):89–95.
- Olsen EA, Hordinsky M, Whiting D, Stough D, Hobbs S, Ellis ML, Wilson T, Rittmaster RS, Dutasteride Alopecia Research Team. 2006. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol. 55(6):1014–1023.
- Roy A, Kucukural A, Zhang Y. 2010. I-TASSER: a unified platform for automated protein structure and function prediction. Nat Protoc. 5(4):725–738.
- Thiboutot D, Harris G, Iles V, Cimis G, Gilliland K, Hagari S. 1995. Activity of the type 1 5α-reductase exhibits regional differences in isolated sebaceous glands and whole skin. J Invest Dermatol. 105(2):209–214.
- Trüeb RM. 2002. Molecular mechanisms of androgenetic alopecia. Exp Gerontol. 37(8-9):981–990.
- Zhang Y, Skolnick J. 2004. Scoring function for automated assessment of protein structure template quality. Proteins Struct Funct Genet. 57(4):702–710.
- Zhou Z, Song S, Gao Z, Wu J, Ma J, Cui Y. 2019. The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia: a systematic review and meta-analysis. CIA. 14:399–406.